These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 11365398

  • 21. Update from the 5th Conference on Retroviruses and Opportunistic Infections.
    Vazquez E.
    Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483
    [Abstract] [Full Text] [Related]

  • 22. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
    Larru B, de Mendoza C, Bellón JM, de José MI, Mellado MJ, Soriano V, Muñoz-Fernandez MA, Ramos JT.
    BMC Infect Dis; 2007 Jun 10; 7():55. PubMed ID: 17559687
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Predictors of treatment failure during highly active antiretroviral therapy (racing trial).
    Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, Lauenroth-Mai E, Moll A, Schranz D, Moecklinghoff C, Arastéh K.
    Eur J Med Res; 2002 Aug 30; 7(8):341-6. PubMed ID: 12204841
    [Abstract] [Full Text] [Related]

  • 25. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F, Kliniek en Virologie van het ATHENA-project.
    Ned Tijdschr Geneeskd; 2001 Aug 18; 145(33):1591-7. PubMed ID: 11534377
    [Abstract] [Full Text] [Related]

  • 26. [Salvage therapy in HIV infection].
    Salzberger B.
    MMW Fortschr Med; 2004 Apr 26; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V, Descamps D, Yeni P.
    AIDS Rev; 2002 Apr 26; 4(3):128-39. PubMed ID: 12416447
    [Abstract] [Full Text] [Related]

  • 29. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
    Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D.
    J Infect Dis; 2002 Sep 01; 186(5):626-33. PubMed ID: 12195349
    [Abstract] [Full Text] [Related]

  • 30. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Murphy MD, Marousek GI, Chou S.
    J Clin Virol; 2004 May 01; 30(1):62-7. PubMed ID: 15072756
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response.
    Casado JL, Moreno A, Sabido R, Martí-Belda P, Antela A, Dronda F, Perez-Elías MJ, Moreno S.
    AIDS; 2003 Jan 24; 17(2):262-4. PubMed ID: 12545089
    [Abstract] [Full Text] [Related]

  • 33. Any toxic relief in sight? The induction/maintenance approach to therapy.
    Gomez E.
    Newsline People AIDS Coalit N Y; 1998 Sep 24; ():33. PubMed ID: 11367488
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.